



STILL A PLACE FOR PILLS – DON'T IVF EVERYTHING

Jeff Roberts M.D.
Co-Director, Pacific Centre for Reproductive Medicine

PCRM Pacific Centre for Reproductive Medicine


Objectives

PCRM Pacific Centre for Reproductive Medicine


- 1 Clomiphene citrate and Letrozole
- 2 Infertility Case Studies
- 3 Unexplained Infertility
- 4 PCOS
- 5 Ovulatory dysfunction

www.pacificfertility.ca


Clomiphene Citrate



- Non-steroidal triphenyl ethylene derivative with similar structure to estrogen
- Antagonist at estrogen receptor in hypothalamus, increasing FSH/folliculogenesis via GnRH
- Antagonist at cervix and endometrium (may offset superovulatory effects)
- Dose: 50-150 mg PO x 5 days
- Egg yield: 2 follicles for all doses
- $T_{1/2}$ weeks (metabolites)
- Side effects (20% discontinue use)
 - Mood disturbances (70-80%)
 - Hot flushes (10-30%)
 - Dizziness/nausea (5%)
 - Visual disturbances (stop medication) (<2%)



www.pacificfertility.ca



www.pacificfertility.ca

Letrozole

PCRM Pacific Centre for Reproductive Medicine

- Highly selective non-steroidal third-generation aromatase inhibitor (final step in estrogen synthesis) - suppresses 97-98% activity
- Hypoestrogenic state induces increasing FSH/folliculogenesis via GnRH
- Dose: 2.5-7.5 mg PO x 5 days
- Egg yield:
 - 1 follicle with 5 day protocols
 - 2 follicle with 9 day protocols
- $T_{1/2} \sim 45$ hours
- Side effects (rarely discontinue)
 - Hot flushes (20%)
 - Headache
 - Fatigue (22%)
 - GI disturbance
- Not antagonist in reproductive tract

Holtzer et al. Fertil Steril 2006; 85:277-84

www.pacificfertility.ca

Letrozole

PCRM Pacific Centre for Reproductive Medicine

- Only FDA-approved as adjuvant hormone therapy for post-menopausal breast cancer
- Malformation concerns never appear in peer reviewed publication but Novartis issued a black label warning regardless in response to a single abstract suggesting risk
- Health Canada will not officially approve use of letrozole for fertility, but taking position of non-refusal (unofficially supportive)



www.pacificfertility.ca



Case # 1


- 37 y.o. G1A1
- 2 years infertility
- SAB x 1 uncomplicated
- Regular cycles q 28 days
- Positive OPKs most months and timing ok
- Investigations:
 - SA: normal
 - HSG: normal
 - Ovarian reserve testing: AMH 9 pmol/L, FSH 8 IU/L, AFC 10

Unexplained Infertility

- Traditionally diagnosis made after basic infertility evaluation fails to reveal an obvious abnormality (ovulation, adequate sperm and patent tubes)
- Up to 30% of infertility couples
- Average cycle fecundity 2 to 4%
- Pregnancy rates decline with increasing age and duration of infertility
- Egg aneuploidy likely cause in most cases - no test







Clomiphene Citrate alone

PCRM Pacific Centre for Reproductive Medicine

- Expectant vs CC – 2.8% vs 2.3% per cycle
- 8% multiple pregnancy rate (anovulation studies)

Clomiphene citrate should not be used alone for unexplained infertility

Hughes et al. Cochrane Rev 2010
 Battacharya et al. BMJ 2008;337:a716

www.pacificfertility.ca

Clomiphene + IUI PCRM Pacific Centre for Reproductive Medicine

- IUI may counter cervical factor created by CC
- Clinical pregnancy rate 8%/cycle compared to 2-4% with expectant¹
- Meta-analysis (6 RCTs) demonstrate 4-5X higher pregnancy rates compared to natural cycle²
- Cochrane review (2016) (14 RCTs) – no difference between CC/IUI or FSH/IUI and natural cycle

“Given ease, cost and low rate of multiple pregnancy CC/IUI has become a standard 1st line therapy for UEI” - CFAS CPG Committee

1. Guzick et al Fertil Steril. 1998;70(2):207-13
2. Costello et al. Aust NZ J OBGYN 2004;44:93-102
3. Veltman-Verhulst et al. Cochrane Rev 2016

www.pacificfertility.ca

CC or LTZ + IUI vs Expectant Management for UEI - RCT PCRM Pacific Centre for Reproductive Medicine


Randomized unfavourable prognosis patients to 3 cycles of:

- IUI with CC 50-150 mg days 2-6 or LTZ 2.5-7.5 mg , days 2-6
- Expectant management

3X higher live birth rate with CC/LTZ

Farquhar et al. Lancet 2018;391:441-50

www.pacificfertility.ca



- ### Extended LTZ for Unexplained Infertility
- PCRM Pacific Centre for Reproductive Medicine
- Retrospective analysis of PCRM experience with extended LTZ ± IUI for UEI
 - N = 141
 - 2.5 mg PO cycle days 1 to 9
 - Midcycle ultrasound assessment
 - Average age 35.3
 - Maximum of 6 cycles, average 3.2
 - Cumulative pregnancy rate: **14.3%**
 - Multiple pregnancy rate: 10.0%
 - Mean # follicles 1.9
- Harjee et al. CFAS Annual Meeting 2017
- www.pacificfertility.ca

Management of Unexplained Infertility

PCRM Pacific Centre
for Reproductive
Medicine

- Consider expectant management after completion of work-up, particularly if there has been a surgical correction (e.g. polyp)
- Letrozole 2.5 mg PO QD cycle days 1 to 9 ± IUI
- Clomiphene citrate 100 mg PO QD cycle days 3 to 7 + IUI

www.pacificfertility.ca

Case # 2

PCRM Pacific Centre
for Reproductive
Medicine

- 29 y.o. G0
- Irregular cycles, q 3-4 months
- Complaints of oily skin and acne
- Difficulty detecting ovulation
- Investigations:
 - SA: normal
 - HSG: patient declined
 - Ovarian reserve testing: AMH 29 pmol/L, FSH 4 IU/L, AFC 25

www.pacificfertility.ca

Polycystic Ovary Syndrome

PCRM Pacific Centre for Reproductive Medicine

- Criteria (2 of 3)¹
 - Anovulation – oligo (>70%), poly (<2%), or eumenorrhea (20-30%)
 - Polycystic ovaries
 - Hyperandrogenism (clinical or biochemical)
- 80% of women with anovulatory infertility
- Clinical features broader
 - Reproductive (infertility, pregnancy-related risks)
 - Metabolic (obesity, insulin resistance, GDM, cardiovascular risks)
 - Psychological (anxiety, depression, impaired quality of life)

1. ESHRE/ASRM, 2004 Rotterdam Criteria
2. National Institute of Health (NIH) 1990 criteria

www.pacificfertility.ca

Polycystic Ovary Syndrome - Work up

PCRM Pacific Centre for Reproductive Medicine

- Menstrual history
 - Irregular cycles (>35 or <21) continuing for >2 years after onset of menarche
- Pelvic ultrasound
 - PCO = >12 antral follicles per ovary, volume >10cm³
- No HSG?
- Assessment of ovulation
 - Mid-luteal progesterone (<10 nmol/L)
 - Follicle tracking
- Early follicular FSH, LH and estradiol
- AMH (>35 pmol/L)
- Assessment for hyperandrogenism
 - Clinical
 - Biochemical (testosterone, DHEAS, 17OHP)
- DM screen

www.pacificfertility.ca

Polycystic Ovary Syndrome - Treatment

PCRM Pacific Centre for Reproductive Medicine

- Weight loss (5-10%)
 - Lower risk pregnancy
 - Improved response to ovulation induction and natural conception
- Bariatric surgery (suggested with BMI >35 and failed weight loss > 1 yr)
- Clomiphene citrate (no IUI)
 - 50-150 mg PO cycle days 3 to 7
- Aromatase inhibitors (no IUI)
 - 2.5-7.5 mg PO cycle days 3 to 7
- Metformin
- Gonadotropins
- Laparoscopic ovarian drilling

Balen et al. Hum Reprod Update 2016;22(6):6687-708

www.pacificfertility.ca

Goals of Ovulation Induction

PCRM Pacific Centre for Reproductive Medicine

- Restoration of a normal menstrual cycle
 - Predictable ovulation
 - Regular menses
- Singleton pregnancy/monofollicular response
- Avoidance of gonadotropins

www.pacificfertility.ca

Clomiphene Citrate

- Starting dose 50 mg PO cycle days 3-7 or 5-9, with incremental 50 mg increase if no response
- 75% of pregnancies occur in first three cycles and few occur after 6 months
- 10-15% multiple pregnancy rate
- Ovulation rate 60-90% but only 10-40% conceive
 - Co-release of LH with FSH
 - Anti-estrogenic effects on endometrium and cervical mucous

Kousta et al. Hum Reprod Update 1997;3:359-365

www.pacificfertility.ca

Letrozole vs Clomiphene for PCOS

N=750
P=0.01

Days from Randomization to Live Birth

750 women 1:1 ratio:

- CC 50-150 mg days 3 to 7
- LTZ 2.5-7.5 mg days 3 to 7

Cumulative ovulation rates:

- CC: 48.3%
- LTZ: 61.7% (P<0.001)

Multiple pregnancy rates:

- CC: 7.4%
- LTZ: 3.4%

Letrozole associated with higher live birth and ovulation rates

Legro et al. NEJM 2014;371:119-29

www.pacificfertility.ca

PCRM Pacific Centre
for Reproductive
Medicine

Aromatase inhibitors for subfertile women with polycystic ovary syndrome (Review)

Franik S, Kremer JAM, Nelen WLD, Farquhar C

<p>N = 2800+</p> <p>Clinical pregnancy OR 1.40, 95% CI: 1.18-1.65</p> <p>Live birth rate OR 1.64, 95% CI: 1.32-2.04</p> <p>Multiple pregnancy OR 0.38, 95% CI: 0.17-0.84</p>	<p>Letrozole associated with higher PR and lower multiple rate</p>
--	--

www.pacificfertility.ca

PCRM Pacific Centre
for Reproductive
Medicine


Ovulation Induction Monitoring

- Ovulation predictor kits
 - False positives if starting too early
- Midluteal progesterone levels (>10 nmol/L)
 - Stop measuring once effective dose established and patient regular
 - Absolute level of no value just + or -
- Monitoring follicular phase (starting cycle days 10):
 - Gold standard for diagnosing anovulation¹:
 - Establishing lack of response early
 - Useful if patient doesn't get positive OPKs
 - Lowering risk multiple gestation
 - Does NOT increase pregnancy rate
 - Costly
 - Patient fatigue
- Ovulation triggering of no benefit²⁻³

STAY HOME

1. Ecochard et al. BJOG 2001;108:822-9
2. Kyrrou et al. RBMO 2012;25:278-283
3. Agarwal et al. Hum Reprod 1995;10:328-331

www.pacificfertility.ca



Management of PCOS PCRM Pacific Centre for Reproductive Medicine

1. Lifestyle modifications
2. Letrozole:
 - Start dose 2.5 mg PO QD cycle days 3 to 7
 - Increase by 2.5 mg increments if no response
 - Maximum dose 7.5 mg
3. Clomiphene Citrate:
 - Starting dose 50 mg PO QD cycle days 3 to 7
 - Increase by 50 mg increments if no response
 - Maximum dose 150 mg (minimal evidence for >100 mg)

www.pacificfertility.ca

Case # 3 PCRM Pacific Centre for Reproductive Medicine

- 33 y.o. G0
- Cycles q 26-32 days
- OPKs occasionally faintly positive
- Investigations:
 - SA: low normal morphology
 - HSG: normal
 - Ovarian reserve: AMH 28 pmol/L, FSH 6 IU/L, AFC 32

www.pacificfertility.ca

Traditional Thinking on Ovulation PCRM Pacific Centre for Reproductive Medicine

Ovulatory cycles have regular, predictable and consistent volume and duration

- Eumenorrhea defined by a wide range of lengths (21-35) established through epidemiologic studies

Anovulatory cycles are irregular and unpredictable

- Oligomenorrhea defined as >35 days

Malcolm et al. Obstet Gynecol 2003;102(2):317-318
 Cole et al. Fertil Steril 2009;91:522-7

www.pacificfertility.ca

Occult Ovulatory Dysfunction


PCRM Pacific Centre
for Reproductive
Medicine

- PCOS may be a continuum
- Approximately 20% women have menstrual irregularity 2/3 do not meet criteria for PCOS²
- “Regular” menses does not exclude anovulation (mild phenotype in 10-15%)¹

1. Sjaarda et al. Fertil Steril 2018;109:540-8
2. Soloman et al. JAMA 2001;286:2421-6

www.pacificfertility.ca

Occult Ovulatory Dysfunction

PCRM Pacific Centre
for Reproductive
Medicine

N=283

Cycle length: 28.1 days (range 22-44)
Mean time to ovulation: 14.8 days (range 9-33)
Mean postovulatory phase: 13.3 days (range 7-17)

LH surges > 3 days associated with lower E, P and smaller CL

LH surges with multiple peaks associated with smaller follicles and lower peak LH levels

Direito et al. Fertil Steril 2013;99(1):279-85

www.pacificfertility.ca

Occult Ovulatory Dysfunction

PCRM Pacific Centre for Reproductive Medicine

Luteinized unruptured follicles (LUF) – failure of follicle to rupture at the expected follicular-luteal transition:¹

- Slower growth as approaches maximum size
- Lower peak FSH and LH levels
- Premature rise of progesterone (premature luteinization)

Luteal phase defect

- Estrogen deficiency will lead to poor priming of endometrium (ER PR upregulation)
- Progesterone deficiency leads to inadequate luteinization
- Short cycles (<25 days) and short luteal phase (<11 days) associated with subfertility²
- Women with unexplained infertility have lower progesterone during luteal phase³

1. Bashir et al. Hum Reprod 2018;33(6):1130-1140
 2. Crawford et al. Fertil Steril 2016;107(3):749-55
 3. Blacker et al. Fert Steril 1997;67:437-42

Occult Ovulatory Dysfunction

PCRM Pacific Centre for Reproductive Medicine

Risk factors for oligo/anovulation:

- High AMH (>30 pmol/L)
 - 18-20% rate anovulation
 - AMH reduces sensitivity of granulosa to FSH
 - AMH receptors expressed on GnRH neurons in hypothalamus
- Hyperandrogenism
 - 20-50% have chronic anovulation¹
- Polycystic ovaries = high ovarian reserve ≠ PCOS²
 - 20-30% of population
 - Very common in young patients
 - Approximately 20% have PCOS
- Insulin resistance/metabolic abnormalities – poorly studied but likely an association

1. Chang et al. Fertil Steril 2005;83:1717-23
 2. Azziz et al Fertil Steril 2009;91(2):456-88

Management Occult Ovulatory Dysfunction

PCRM Pacific Centre
for Reproductive
Medicine

1. Lifestyle modifications

2. Letrozole:

- Start dose 2.5 mg PO QD cycle days 3 to 7
- Increase by 2.5 mg increments if no response
- Maximum dose 7.5 mg

3. Clomiphene Citrate:

- Starting dose 50 mg PO QD cycle days 3 to 7 for anovulation
- Increase by 50 mg increments if no response
- Maximum dose 150 mg (minimal evidence for >100 mg)

www.pacificfertility.ca

Case # 4

PCRM Pacific Centre
for Reproductive
Medicine

- 28 y.o. G0
- Triathlete
- No period since stopping OCs 2 years ago
- No withdrawal bleed to Provera 10 mg x 10 days
- Investigations:
 - SA: normal
 - HSG: not performed
 - Ovarian reserve: AMH 20 pmol/L, FSH <1 IU/L, LH <1 IU/L, AFC 16

www.pacificfertility.ca

Hypothalamic Amenorrhea

PCRM Pacific Centre
for Reproductive
Medicine

- Limited central function secondary to disrupted GnRH release and low FSH and LH secretion
- Risk factors:
 - Low BMI
 - Exercise
 - Stress
- Diagnosis
 - Failed progestin challenge (hypoestrogenic)
 - Low serum gonadotropin levels, normal prolactin
 - Normal cranial imaging
- Management
 - Lifestyle modification
 - Gonadotropins (FSH + LH)/IUI or IVF
 - Not CC or LTZ

www.pacificfertility.ca

Take Home Messages

PCRM Pacific Centre
for Reproductive
Medicine

- More eggs = more babies but also more risk – optimal number limited by safety
- Consider expectant management after the diagnosis of unexplained infertility
- Clomiphene traditionally first line for ovulatory disorders
- Based on existing evidence, letrozole first line for ovulatory disorders
- Clomiphene/IUI and letrozole acceptable for unexplained infertility
- Have a low threshold for starting letrozole in any patient with suggestion of ovulatory dysfunction

www.pacificfertility.ca

Take Home Messages PCRM Pacific Centre for Reproductive Medicine

When to refer to REI

- Completion of treatment course:
 - Unexplained infertility: 3-6 months
 - Ovulatory disorders: 6 months of ovulatory cycles
- Hypothalamic amenorrhea
- Advanced age (>37)
- Poor ovarian reserve testing

www.pacificfertility.ca



Questions?

STILL A PLACE FOR PILLS – DON'T IVF EVERYTHING

Jeff Roberts M.D.
Co-Director, Pacific Centre for Reproductive Medicine

PCRM Pacific Centre for Reproductive Medicine